Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05610085
Other study ID # FD-R-6335
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 24, 2023
Est. completion date December 31, 2027

Study information

Verified date June 2024
Source University of California, San Diego
Contact Sonya G Wang, M.D.
Phone 612-301-1454
Email sgwang@umn.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this study is to determine the maximum safe tolerated dose of LEV in the treatment of neonatal seizures. Our hypothesis is that optimal dosing of Levetiracetam (LEV) to treat neonatal seizures is significantly greater than 60mg/kg. This study will be an open label dose-escalation, preliminary safety and efficacy study. There will be a randomized control treatment component. Infants recognized as having neonatal seizures or as being at risk of developing seizures will be recruited and started on continuous video EEG monitoring (CEEG). Eligibility will be confirmed and consent will be obtained. In the first 2 phases of the study, neurologists will identify neonates with mild-moderate seizure burden (less than 8 minutes cumulative seizure activity per hour), appropriate for study with LEV, and exclude patients with higher seizure burden where treatment with PHB is more appropriate. Phase 3 of the dose escalation will only proceed if additional efficacy of LEV has been demonstrated in phases 1 and 2. In Phase 3 we will recruit neonates with seizures of greater severity up to 30 minute seizure burden/hour. This will make the final results of study more generalizable. If seizures are confirmed, enrolled subjects will receive 60mg/kg of LEV. Subjects whose seizures persist or recur 15 minutes after the first infusion is complete, subjects will then be randomized in the dose escalation study. Patients in the dose escalation study will be randomly assigned to receive either higher dose LEV or treatment with the control drug PHB in a 3:1 allocation ratio, stratified by site. Funding Source- FDA OOPD


Description:

Aims/Hypotheses: Primary Aim: To determine the recommended maximal safe dose of LEV in the setting of neonatal seizures of mild to moderate severity. If 60mg/kg LEV does not control seizures, subjects will be randomised to receive either additional LEV or PHB. LEV dose will be escalated in 30mg/kg increments to a maximal dose of 150mg/kg total loading dose. We will use a continual reassessment method to determine the maximal safe and tolerated dose. Secondary/exploratory aims: - To study the pharmacokinetics of high dose LEV in neonates with seizures of mild to moderate severity. - To estimate the additional efficacy of higher doses of LEV in neonates with seizures of mild to moderate severity. - To improve technologies for the prompt detection of neonatal seizures: We will assess the latest version of Persyst's neonatal seizure detector. Research Design This is a Phase IIb, open label dose-escalation, preliminary safety and efficacy study. An active drug treatment control arm (PHB group) is included in the study design. This study is not designed or powered to compare high dose LEV and PHB groups, however, the randomized control group will help with interpretation of adverse events and seizure cessation efficacy seen in the high dose escalation group. This is particularly important because of the high rates of morbidity in neonates with seizures. 24-hour seizure control endpoint: cEEG reviewed by a neurophysiologist will be used for assessing 24-hour seizure control. Treatment will be considered effective in achieving 24-hour seizure control if there is a seizure burden less than 30 seconds in the 24 hours following the dose. Change in seizure burden in 2-hour post treatment period will also be assessed. Intervention If seizure activity occurs participants will be enrolled and will receive 60mg/kg LEV. If seizures continue babies will then be randomised to receive either: - Additional LEV at a higher dose (30 mg/kg, 60 mg/kg, or 90 mg/kg depending on the stage of the study), OR - PHB at 20-40 mg/kg. Maintenance treatment will continue for 5 days, either IV or orally if baby is tolerating feeds. LEV discontinuation or addition of PHB: there are multiple criteria for transition to, or addition of, PHB treatment if required for seizure control.


Recruitment information / eligibility

Status Recruiting
Enrollment 133
Est. completion date December 31, 2027
Est. primary completion date July 1, 2027
Accepts healthy volunteers No
Gender All
Age group N/A to 1 Month
Eligibility Inclusion Criteria: - at risk for seizures or suspected to be having seizures; - all seizure aetiologies except correctable metabolic abnormalities such as hypoglycaemia and hypocalcaemia; - Term neonates (corrected gestational age between 35 and 44 weeks, postnatal age less than 28 days); - weight > 2200g. - Parental ability to comprehend and provide written informed consent Exclusion Criteria: - Cumulative seizure burden of 8 minutes/ hour or more in phases 1 and 2, Cumulative seizure burden of 30 minutes/hour or more in phase 3; - Renal failure defined as anuria in the first 24 hours of life; - Subjects in whom death seems imminent; - Seizures caused by correctable metabolic abnormality, such as hypocalcaemia, hypoglycaemia.

Study Design


Intervention

Drug:
Levetiracetam Injection
Neonates will be treated with intravenous levetiracetam 60mg/kg for first line management of seizures, and if seizures persist will be randomized to receive higher dose Levetiracetam or standard of care phenobarbital
Phenobarbital Sodium Injection
Standard of care for neonatal seizures

Locations

Country Name City State
New Zealand Auckland City Hospital Auckland
New Zealand Middlemore Hospital Auckland
United States University of Minnesota Minneapolis Minnesota
United States University of California, San Diego San Diego California

Sponsors (6)

Lead Sponsor Collaborator
University of California, San Diego Auckland City Hospital, Middlemore Hospital, New Zealand, Rady Children's Hospital, San Diego, University of Auckland, New Zealand, University of Minnesota

Countries where clinical trial is conducted

United States,  New Zealand, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary endpoint is the maximum safe and tolerated dose of Levetiracetam A continual reassessment method will be used to determine the maximal safe and tolerated dose 4 years
Secondary Levetiracetam CL Population pharmacokinetic parameters for LEV Clearance (CL)will be calculated 4 years
Secondary Levetiracetam Vd Population pharmacokinetic parameters for LEV Volume of distribution (Vd) will be calculated 4 years
Secondary Adverse event rates Rates of adverse events seen with high dose LEV treatment will be reported and compared to rates seen in PHB control arm. 4 years
Secondary Long-term outcome Rates of adverse long-term outcome ( Death or Disability at 24 months) will be compared between treatment arms 8 years
Secondary Seizure burden reduction Number of patients with at least 50% seizure burden reduction post treatment will be compared between randomized treatment arms 4 years
Secondary Seizure freedom rates Number of patients who become seizure free for 24 hours post treatment will be compared between the randomized treatment groups in each stage of the study 4 years
Secondary Estimate of efficacy of higher dose LEV Assuming no dose limiting toxicity is demonstrated and the study proceeds to completion, 50 subjects will be treated at 120mg/kg or higher dosing level. This sample size will give satisfactory power for estimating additional efficacy of higher doses. For example, if we document an additional response rate of 15%, this sample size will provide a 95% confidence interval (0.051, 0.248) around that estimate. 4 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05048550 - Babies in Glasses; a Feasibility Study. N/A
Recruiting NCT05514340 - Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy Phase 2
Recruiting NCT05836610 - Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates Phase 4
Completed NCT03024021 - Cerebral Oxymetry and Neurological Outcome in Therapeutic Hypothermia
Completed NCT01913340 - Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO) Phase 1/Phase 2
Enrolling by invitation NCT02260271 - Florida Neonatal Neurologic Network
Terminated NCT01192776 - Optimizing (Longer, Deeper) Cooling for Neonatal Hypoxic-Ischemic Encephalopathy(HIE) N/A
Completed NCT06344286 - The Effects of Minimal Enteral Nutrition on Mesenteric Blood Flow and Oxygenation in Neonates With HIE N/A
Recruiting NCT05901688 - Umbilical Cord Abnormalities in the Prediction of Adverse Pregnancy Outcomes
Recruiting NCT02894866 - Hyperbaric Oxygen Therapy Improves Outcome of Hypoxic-Ischemic Encephalopathy N/A
Recruiting NCT03682042 - Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries Developmental Follow Up N/A
Recruiting NCT03657394 - Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries N/A
Withdrawn NCT03681314 - Umbilical Cord Milking in Neonates Who Are Depressed at Birth-Developmental Follow Up (MIDAB-FU) N/A
Completed NCT03485781 - Propofol-induced EEG Changes in Hypoxic Brain Injury
Not yet recruiting NCT06429007 - A Safety and Feasibility Trial Protocol of Metformin in Infants After Perinatal Brain Injury Phase 2
Recruiting NCT05568264 - Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit N/A
Not yet recruiting NCT06448780 - Dose Optimization of Caffeine for HIE Phase 1
Completed NCT02264808 - Developmental Outcomes
Completed NCT05687708 - Effect of Non-nutritive Sucking on Transition to Oral Feeding in Infants With Asphyxia N/A
Recruiting NCT06195345 - Individual Cerebral Hemodynamic Oxygenation Relationships (ICHOR 1)